Company intelligence / Profile preview

Foresight Diagnostics

Boulder, Colorado, United Statesforesight-dx.com ↗

Ownership: Private
Development stage: Commercial

Overview

Foresight Diagnostics is developing ultra-sensitive liquid biopsy tests for minimal residual disease (MRD) detection, with a focus on improving cancer diagnostics and treatment outcomes. Their technology has shown significant clinical and regulatory progress.

Therapeutic areas: Oncology
Modalities: Liquid BiopsyCirculating Tumor DNA (ctDNA)
Industry: Molecular Diagnostics

Drug pipeline

1 asset

Foresight CLARITY

Commercial

Indications: Lymphoma, Solid tumors

Partnerships

Allogene Therapeuticsmultiple biopharma and academic partners

Beyond the preview

Go deeper on Foresight Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Foresight Diagnostics.